Product Code: DICL0008
Immune Checkpoints are molecules that are important for maintaining, modulating and regulating the immune responses. Under normal physiological conditions, immune checkpoints are crucial for the maintenance of self-tolerance and to protect tissues from damage during pathogenic infection. Immune Checkpoints regulation and activation of T lymphocytes depend on signaling by the T cell receptor (TCR) and also by co-signaling receptors that deliver negative or positive signals. The expression of stimulatory immune-checkpoint proteins can be down-regulated by tumors. So, activation of this stimulatory immune checkpoint is an important step to eradicate the cancer.
"Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2020" report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Immune Checkpoints Activators, including the pipeline products in this space. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the information related to several technologies in development of the molecules based on the Immune Checkpoints Activators mechanism. The report provides the understanding of the unmet needs of the Immune Checkpoints Activators market.
DelveInsight has made a strong presence in the market with 100+ Reports on various Indications & different Mechanism of Action (MOA). DelveInsight Report, Immune Checkpoints Activators - Competitive Landscape, Pipeline and Technology Analysis, 2020 has received great response and feedback from clients.
Future competitive landscape of Immune Checkpoints Activators is estimated to be very strong. Key emerging drugs including Nektar Therapeutics' NKTR-214 and others are going to be Blockbuster in the upcoming years.
The report provides insights into:
- A number of companies developing therapies of Immune Checkpoints Activators with aggregate therapies developed by each company for the same.
- Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Immune Checkpoints Activators.
- Analyses key players involved in Immune Checkpoints Activators targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Active pipeline therapies assessment under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detail analysis of collaboration (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future developments of Immune Checkpoints Activators.
- Detailed information regarding the technologies developed for the Immune Checkpoints Activators.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.
Immune Checkpoints Activators Analytical Perspective by DelveInsight
- In-depth Immune Checkpoints Activators Analysis: Assessment of Products
This report provides an in-depth commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, agreements, licensing, and acquisition - deal value trends. The sub-segmentation is described in the report which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.
- Immune Checkpoints Activators Clinical Assessment of Products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this mechanism of action.
Scope of the Report
- The Immune Checkpoints Activators report provides an overview of this mechanism of action, role, significance, pathway, types, and clinical application of IDH inhibitors.
- Therapeutic Assessment: Therapeutic pipeline activity and assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of therapeutic products for Immune Checkpoints Activators with key coverage of developmental activities, including collaborations, agreements, licensing, mergers and acquisition, funding, designations, technology and other product-related details.
- In-depth Immune Checkpoints Activators research and development progress and trial details results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Immune Checkpoints Activators.
- It also includes patent expiry details impact on market after expiry.
- Key topics covered include strategic competitor assessment, opportunities, unmet needs, market growth factors, barriers and challenges of the Immune Checkpoints Activators market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Immune Checkpoints Activators R&D. The Immune Checkpoints Activators therapies under development are focused on novel approaches to treat/improve the disease condition.
- There are many companies involved in developing therapies for Immune Checkpoints Activators. Launch of emerging therapies of Immune Checkpoints Activators will significantly impact the market.
- A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Immune Checkpoints Activators.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late-stage of development for the treatment of Immune Checkpoints Activators includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
- The report provides the detailed analysis of 10+ products along with 8+ companies involved.
- Nektar Therapeutics
And many more …
- What are Immune Checkpoints Activators, their role and significance in the treatment of disease conditions?
- How many therapies are developed by each company for Immune Checkpoints Activators to treat disease conditions?
- What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Immune Checkpoints Activators therapies?
- Which are the dormant and discontinued products and the reasons for dormancy and discontinuation?
- What is the unmet need for current therapies developed on the basis of this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune Checkpoints Activators and their status?
- What are the current and upcoming technologies for the Immune Checkpoints Activators?
Table of Contents
1. Report Introduction
2. Immune Checkpoints Activators
- 2.1. Immune Checkpoints Activators Overview
- 2.2. Immune Checkpoints Activators Types
- 2.3. Immune Checkpoints Activators Structure
- 2.4. Immune Checkpoints Activators Mechanism of Action
- 2.5. Immune Checkpoints Activators Application
3. Competitive Landscape
4. Immune Checkpoints Activators - DelveInsight's Analytical Perspective
- 4.1. In-depth Commercial Assessment
- 4.1.1. Immune Checkpoints Activators Companies Collaborations, Licensing, Acquisition - Deal Value Trends
- 22.214.171.124. Assessment Summary
- 4.1.2. Immune Checkpoints Activators Collaboration Deals
- 126.96.36.199. Company-Company Collaborations (Licensing/Partnering) Analysis
- 188.8.131.52. Company-University Collaborations (Licensing/Partnering) Analysis
- 184.108.40.206. Immune Checkpoints Activators Acquisition Analysis
5. Therapeutic Assessment
- 5.1. Clinical Assessment of Pipeline Drugs
- 5.1.1. Assessment by Stage of Development
- 5.1.2. Assessment by Product Type (Mono/Combination)
- 220.127.116.11. Assessment by Stage and Product Type
- 5.1.3. Assessment by Route of Administration
- 18.104.22.168. Assessment by Stage and Route of Administration
- 5.1.4. Assessment by Molecule Type
- 22.214.171.124. Assessment by Stage and Molecule Type
- 5.1.5. Assessment by MOA
- 126.96.36.199. Assessment by Stage and MOA
- 5.1.6. Assessment by Target
- 188.8.131.52. Assessment by Stage and Target
6. Pipeline Therapeutics
- 6.1. Comparative Analysis
7. Late-Stage Products (Phase-III)
8. Mid-Stage Products (Phase-II)
9. Early-Stage Products (Phase-I)
10. Preclinical and Discovery Stage Products
11. Immune Checkpoints Activators Emerging Drug Profiles
- 11.1. NKTR-214: Nektar Therapeutics
- 11.1.1. Product Description
- 11.1.2. Research and Development
- 184.108.40.206. Clinical Studies
- 11.1.3. Product Development Activities
- 11.1.4. Tabulated Product Summary
- 220.127.116.11. General Description Table
Many more drugs with detailed profiles provided in the report …
12. Immune Checkpoints Activators Key Companies
13. Immune Checkpoints Activators Key Products
14. Inactive Products
- 14.1. Dormant Products
- 14.1.1. Reason for Dormancy
- 14.2. Discontinued Products
- 14.2.1. Reason for Discontinuation
15. Immune Checkpoints Activators - Unmet Needs
16. Immune Checkpoints Activators - Future Perspectives and Conclusion
17. Immune Checkpoints Activators Analyst Views
19. Report Methodology
- 19.1. Secondary Research
- 19.2. Expert Panel Validation
List of Tables
- Table 1 Assessment Summary
- Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis
- Table 3 Immune Checkpoints Activators Acquisition Analysis
- Table 4 Assessment by Phase of Development
- Table 5 Assessment by Product Type (Mono/Combination)
- Table 6 Assessment by Stage and Product Type
- Table 7 Assessment by Route of Administration
- Table 8 Assessment by Stage and Route of Administration
- Table 9 Assessment by Molecule Type
- Table 10 Assessment by Stage and Molecule Type
- Table 11 Assessment by MOA
- Table 12 Assessment by Stage and MOA
- Table 13 Assessment by Target
- Table 14 Assessment by Stage and Target
- Table 15 Late-Stage Products (Phase-III)
- Table 16 Mid-Stage Products (Phase-II)
- Table 17 Early-Stage Products (Phase-I)
- Table 18 Preclinical and Discovery Stage Products
- Table 19 Inactive Products
- Table 20 Dormant Products
- Table 21 Discontinued Products
List of Figures
- Figure 1 Immune Checkpoints Activators Structure
- Figure 2 Immune Checkpoints Activators Mechanism
- Figure 3 Immune Checkpoints Activators Types
- Figure 4 Immune Checkpoints Activators Clinical Significance
- Figure 5 Immune Checkpoints Activators companies collaborations, Licensing, Acquisition - Deal Value Trends
- Figure 6 Company-Company Collaborations (Licensing/Partnering) Analysis
- Figure 7 Immune Checkpoints Activators Acquisition Analysis
- Figure 8 Assessment by Phase of Development
- Figure 9 Assessment by Product Type (Mono/Combination)
- Figure 10 Assessment by Stage and Product Type
- Figure 11 Assessment by Route of Administration
- Figure 12 Assessment by Stage and Route of Administration
- Figure 13 Assessment by Molecule Type
- Figure 14 Assessment by Stage and Molecule Type
- Figure 15 Assessment by MOA
- Figure 16 Assessment by Stage and MOA
- Figure 17 Late-Stage Products (Phase-III)
- Figure 18 Mid-Stage Products (Phase-II)
- Figure 19 Early-Stage Products (Phase-I)
- Figure 20 Preclinical and Discovery Stage Products
- Figure 21 Inactive Products
- Figure 22 Dormant Products
- Figure 23 Discontinued Products
- Figure 24 Unmet Needs